Method for morphological evaluation of influence of various dosage forms of iron for enternal application on small intestine in experimental animals

FIELD: medicine.

SUBSTANCE: pathohistological examination of the small intestine tissues is performed. Morphological criteria are determined: desquamation of the mucosal epithelium, necrosis of the mucous membrane, arterial-venous hyperemia, hemorrhage, mucosal edema, hemosiderosis of enterocytes, hemosiderosis of phagocytes. Further, the criteria are scored. The degree of influence of medicinal forms of iron on the small intestine (SPK) is calculated according to the claimed formula. The value of SPK from 0 to 1.2 points inclusive is assessed as a mild injury. SPK from 1.3 to 1.9 points inclusive - as an average injury. SPK from 2.0 to 3.0 points inclusive - as a serious injury.

EFFECT: method allows to accurately and simply perform a morphological evaluation of the effect of various medicinal forms of iron for enteral administration on the small intestine in experimental animals by determining the most significant morphological criteria.

2 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: product contains drinking water having an oxidation-reduction potential from minus 600 to minus 50 mV, total mineralisation from 25 to 130 mg/l and pH value from 6.9 to 8.3. A method for producing a lymphatic drainage stimulant involves the advanced treatment of the drinking water by passing it through a semi-permeable membrane having a hole size of 0.0001-0.005 mcm, and the molecular hydrogen saturation of the water under pressure.

EFFECT: implementing the invention is expected to the highly effective and systemic stimulation of the lymphatic drainage of body tissues by intensifying lymph formation and transport accompanied by no adverse irritant effects.

4 cl

FIELD: medicine.

SUBSTANCE: oral pharmacological composition for treating secondary amyloidosis contains alkaloid curcumin, betulin and piperine taken in certain proportions.

EFFECT: composition is effective for treating secondary amyloidosis.

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to methods of treating type 2 diabetes, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia, involving administering an effective amount of an anti-IL-1β antibody or its fragment into an individual, as well as to using the anti-IL-1β antibody or its fragment in preparing a composition applicable for treating the above diseases or conditions.

EFFECT: group of inventions is effective in treating type 2 diabetes mellitus, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia.

67 cl, 13 dwg, 5 tbl, 14 ex

FIELD: veterinary medicine.

SUBSTANCE: composition comprises succinic acid, trace elements in the form of sulphates of iron, copper, cobalt, zinc and additionally comprises methionine and beet-root molasses at the following content of components in 1000 ml of an aqueous solution: succinic acid - 5.0 g, beet-root molasses - 150.0 ml, methionine - 2.0 g, ferrous sulphate - 10.0 g, copper sulphate - 0.1 g, cobalt sulphate - 0.5 g, zinc sulphate - 0.5 g.

EFFECT: use of the claimed composition has a positive effect on the immune-metabolic status and growth activity of piglets.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula: , wherein R1 represents C1-4 alkyl; R2 can be specified in C1-4-alkyl, 6-merous aryl, heteroaryl, partially or completely saturated 6-merous heterocyclyl containing 1 heteroatom N or O, C3-10-cycloalkyl, 6-merous aryl-C1-6-alkyl, heteroaryl-C1-6-alkyl or R1 and R2 together with N to which they are attached, can form a 10-merous heteroaryl or a 5-10-merous heterocyclyl group optionally containing 1 additional heteroatom specified in O, N and S, each of which can be optionally substituted, R5 is specified in H, C1-2-alkyl, halogen; R6 is specified in a 6-10-merous aryl, 6-9-merous heteroaryl containing 1-2 heteroatoms specified in O and N; R8 represents H; and to compositions for inhibiting a fatty acid amide hydrolase (FAAH) enzyme.

EFFECT: preparing new pharmaceutical compounds.

20 cl, 2 tbl

FIELD: agriculture.

SUBSTANCE: group of inventions relates to the field of animal husbandry and is intended for stimulation of energy metabolic processes and to the method of prevention of patrimonial pathologies and postnatal diseases at cows. The offered composition for stimulation of energy metabolic processes includes the use of amber acid as an energy stimulator. A carbohydrate component is beet treacle, it is used in the following ratio of components per 1 litre: amber acid - 15 g, beet treacle - 500 g, water - the rest. The offered method includes the administration of the named composition a days before calving and during the first hours after calving.

EFFECT: use of the offered group of inventions allows to provide high power activity in organisms of animals during the predicted periods of risk of development of serious pathobiochemical processes, in particular in prenatal and postnatal periods.

2 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents clinical nutrition for prevention, treatment or relief of one or several symptoms, associated with impairment of metabolism or its disorder, which contains composition of polysaccharide high-viscosity dietary fibre, including viscous fibre mixture or its complex, consisting of from 48% to 90% in wt % of glucomannan, from 5 to 20 % in wt % of xanthan gum and from 5% to 30% in wt % of alginate, as well as, at least, one macroelement, selected from the group, consisting of protein carbohydrate and fat, where clinical nutrition is composed in order to provide dose of composition of polysaccharide high-viscosity dietary fibre from 20 g/day to 35 g/day for time period, effective for prevention, treatment and relief of one or several symptoms, associated with impairment of metabolism or its disorder.

EFFECT: invention ensures extension of arsenal of means, preventing, relieving or treating one or several symptoms, associated with impairment of metabolism or metabolic disease.

14 cl, 6 ex, 20 tbl, 48 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relate to field of pharmaceutics, in particular, to pharmaceutical composition for treatment of phenylketonuria, which contains effective quantity of version of Anabaena variabilis (AvPAL) phenylalanine-ammonia-lyase, where claimed version additionally contains polyethylenglycol, as well as pharmaceutically acceptable carrier, which contains stabiliser, where stabiliser represents L-phenylalanine, trans-cinnamic acid or benzoic acid. Also claimed are: method of phenylketonuria treatment and method of reducing phenylalanine concentration in subject's blood.

EFFECT: group of inventions ensure application of prokaryotic PAL, which has higher phenylalanine-converting activity and/or lower immunogenicity in comparison with PAL of wild type.

56 cl, 19 ex, 11 tbl, 19 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining GLP-2 analogues, and can be used in medicine for treating GLP-2-associated disorders. The analogues of GLP-2 with agonistic activity with respect to GLP-2 receptors have been obtained.

EFFECT: invention makes it possible to increase resistance to proteases, which provides the lower clearance of the obtained analogues and prolongation of their bioavailability in comparison with native GLP-2.

29 cl, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate.

EFFECT: invention makes it possible to use aqueous balanced solution as effective means of external washing solution or as carrier solution for compatible electrolytes, nutrients and medications.

11 cl, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.

EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.

27 cl, 8 dwg, 21 tbl, 11 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of probiotic preparation "Prolam" from the first day of life of calves daily for seven days for 5÷7 cm3 orally with colostrum or milk. During prenatal development of calves the probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574) is administered intravaginally to pregnant cows every day for 5-7 days with an interval of 24 hours prior to calving in a dose of 100 cm3.

EFFECT: method is highly effective for prevention of gastrointestinal diseases of newborn calves.

5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics. A medication represents derivatives of glutarimides of the general formula (I) or their pharmaceutically acceptable salts. The invention also relates to pharmaceutical compositions and a method of treatment.

EFFECT: ensured by the application of non-toxic derivatives of the said glutarimides for the treatment of eosinophilic diseases, mainly of an allergic origin.

16 cl, 12 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to neuronal health, neuronal protection and neuronal development, and refers to using a composition containing lactoferrin in the concentration of at least 0.1 g/100 kcal of the composition for treating or preventing diseases related to retarded enteral nervous system and/or disturbed enteral nervous system. The composition is specified in a group consisting of food products, products for animals, pharmaceutical compositions, nutrient formulations, nutrieceuticals, drinks, biologically active food additives, baby's formulas. The composition can additionally contain a protein source, a lipid source and a carbon source. The composition is administered into pregnant women, nursing mothers, premature and mature newborn children, infants, toddlers, children and/or adolescents.

EFFECT: preparing the composition for neuronal protection.

14 cl, 1 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology, namely to obtaining GLP-2 analogues, and can be used in medicine for treating GLP-2-associated disorders. The analogues of GLP-2 with agonistic activity with respect to GLP-2 receptors have been obtained.

EFFECT: invention makes it possible to increase resistance to proteases, which provides the lower clearance of the obtained analogues and prolongation of their bioavailability in comparison with native GLP-2.

29 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: neonatal young pig's liver is homogenised with water; the homogenate is centrifuged for nuclear settlement; the supernatant is heated, centrifuged again; the cooled supernatant is added with cooled ethanol and centrifuged 15-17 h later; the supernatant is dealcoholised; the produced target product is frozen and stored until used in certain environment.

EFFECT: method enables producing the substance stimulating the injured liver repair.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. Presented is the bacteriocin producing strain Lactobacillus pentosus DSM 21980. The strain is used as a therapeutic agent for controlling gram-negative bacteria, preferentially Enterococci, Coliform bacteria, E. coli, reducing or inhibiting the presence thereof. What is also presented is using the strain for the preventive or curative treatment of gastroenteritis or gastoenterocolitis, infections caused by the above bacteria. The strain can be used as an ingredient of the pharmaceutical composition used as a therapeutic agent. Besides, the strain is used as an ingredient of the food composition applicable as a processing additive added to a starter culture for producing dairy products.

EFFECT: group of inventions provides inhibiting the gram-negative bacteria, preferentially E coli.

15 cl, 4 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a citrate of a compound described by formula (II) below, and a pharmaceutical composition containing said citrate.

EFFECT: experimental results of the present inventions prove that said citrate can inhibit activity of phosphodiesterase type 5 and can be used for treating erectile dysfunction, for inhibiting thrombocyte aggregation and treating thrombosis, for reducing pulmonary hypertension and treating cardiovascular diseases, asthma and diabetic gastroparesis.

2 cl

FIELD: medicine.

SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.

EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient's long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.

3 cl, 8 ex

Up!